Efficacy comparison of different guidelines recommending the dosage of paricalcitol in treatment of maintenance hemodialysis complicated with secondary hyperparathyroidism
10.3760/cma.j.cn115455-20240228-00188
- VernacularTitle:不同指南推荐帕立骨化醇用量治疗维持性血液透析合并继发性甲状旁腺功能亢进症的效果对比
- Author:
Ting BAI
1
;
Fan HE
;
Wenjun YANG
Author Information
1. 新疆医科大学第一附属医院肾病三科，乌鲁木齐 830000
- Keywords:
Renal dialysis;
Hyperparathyroidism, secondary;
Guidebooks;
Paricalcitol
- From:
Chinese Journal of Postgraduates of Medicine
2024;47(11):961-966
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the clinical efficacy of different guidelines recommending the dosage of paricalcitol in the treatment of maintenance hemodialysis (MHD) with secondary hyperparathyroidism (SHPT).Methods:The clinical data of 150 patients with MHD combined with SHPT in the First Affiliated Hospital of Xinjiang Medical University from January 2021 to January 2022 were retrospectively analyzed. Among them, 75 patients were treated with the recommended dose of paricalcitol according to European guidelines (European guidelines group), and the starting dose was blood intact parathyroid hormone (iPTH) (ng/L)/80 μg; 75 patients were treated with the recommended dose of paricalcitol according to American guidelines (American guidelines group), and the starting dose was 0.04 μg/kg. The blood calcium, blood phosphorus, creatinine and urea nitrogen before treatment and 1, 3 months after treatment were measured, and the calcium phosphorus product was calculated. The serum alkaline phosphatase (ALP) and iPTH before treatment and 3, 6 months after treatment were measured. The adverse reactions (nausea, vomiting and gastrointestinal discomfort) during the treatment were recorded.Results:There were no statistical difference in the indexes before treatment between two groups ( P>0.05). The blood calcium, blood phosphorus and calcium phosphorus product 1 and 3 months after treatment in American guidelines group were significantly lower than those in European guidelines group, 1 month after treatment: (2.40 ± 0.15) mmol/L vs. (2.53 ± 0.23) mmol/L, (1.70 ± 0.15) mmol/L vs. (2.00 ± 0.30) mmol/L and (4.08 ± 0.42) mmol 2/L 2 vs. (5.06 ± 0.47) mmol 2/L 2, 3 months after treatment: (2.37 ± 0.14) mmol/L vs. (2.50 ± 0.25) mmol/L, (1.65 ± 0.13) mmol/L vs. (1.98 ± 0.27) mmol/L and (3.91 ± 0.40) mmol 2/L 2 vs. (4.95 ± 0.45) mmol 2/L 2, and there were statistical differences ( P<0.01). There were no statistical difference in creatinine and urea nitrogen 1 and 3 months after treatment between two groups ( P>0.05). There was no statistical difference in ALP 3 and 6 months after treatment between two groups ( P>0.05); the iPTH 3 and 6 months after treatment in American guidelines group was significantly lower than that in European guidelines group: (348.20 ± 21.50) ng/L vs. (451.65 ± 28.48) ng/L and (252.64 ± 21.64) ng/L vs. (340.48 ± 19.85) ng/L, and there were statistical differences ( P<0.01). There was no statistical difference in incidence of adverse reactions between two groups ( P>0.05). Conclusions:For patients with MHD combined with SHPT, the recommended dosage of paricalcitol in the American guidelines can significantly improve calcium and phosphorus levels and parathyroid function, without affecting renal function or increasing the incidence of adverse reactions.
